TP53 and melanoma: A375 melanoma cells were used due to their rapid doubling, stable ploidy and success in other shRNA-dropout screens (Sims et al., 2011); they are TP53 wild-type and driven by oncogenic BRAF (V600E) and CDKN2A loss (Forbes et al., 2015).